



Gary Schwartz, MD
 Co-Chair for Experimental Therapeutics Committee
 Columbia University
 177 Fort Washington Avenue, Suite 6GN-435
 New York, NY 10032
 Phone: 212-305-2055
 Email: Schwartzg@columbia.edu

Charles Erlichman, MD, FRCPC, FACP
 Co-Chair for Experimental Therapeutics Committee
 Mayo Clinic
 200 First Street SW
 Rochester, MN 55905
 Phone: 507-266-3200
 Email: Erlichman.charles@mayo.edu

Date: April 26, 2016

To: Experimental Therapeutics Committee

From: Gary Schwartz, M.D.
 Charles Erlichman, M.D.

Re: **Experimental Therapeutics Committee Meeting**

Date: **Friday, May 13, 2016**

Time: **1:00pm-4:30pm Central**

Location: Loews Chicago O'Hare - Rosemont, IL 60018
 Guggenheim 1

Call In Information: (800) 501-8979 / Access Code: 8087368

AGENDA

1. Status update on activated current trials: *Horvath*

a.	A091302	Randomized Phase II study of Sorafenib With or Without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman
b.	A091101	Carboplatin-paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) – A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	J. de Souza
c.	A091105(suspended to accrual)	A Phase III Double Blind Randomized, Placebo Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)	M. Gounder
d.	A091201	Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma	J. Luke
e.	A091202	A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma	M. Pishvaian

f.	A091305	A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel versus Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge
g.	A091304	A Phase I/Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced/Unresectable and/or Metastatic Sarcoma	W. Tap
h.	A091401 (suspended to pre-registration)	Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo

2. Status update on current trials in development: *Schwartz or Horvath*

a.	A091404	A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers	A. Ho
b.	A091602	Randomized Phase II Clinical Trial of Adjuvant Anti-PD-1 Therapy in Patients with High Risk Stage IB-IIC Melanoma	L. Geskin

3. Status of Concepts: *Schwartz or Horvath*

a.	B Smart		E. Horvath
b.	Reversing Resistance to Pazopanib with Histone Deacetylase Inhibition (A091502)		P. Munster
c.	A Randomized Trial of Adjuvant Pembrolizumab, Adjuvant Chemotherapy, or Expectant Observation following Neoadjuvant Pembrolizumab and Surgical Resection of High-Risk Localized or Locoregionally Advanced Mucosal Melanoma.		R. Carvajal A. Shoushtari
d.	PD1/PDL1 + antiCD20 in recurrent Head and Neck Cancer		M. Matsangou
e.	Safety and activity of pembrolizumab, alone or with chemotherapy, combined with radiation in patients with metastatic carcinoma of unknown primary		H. Yoon
f.	NY-ESO		S. Robinson
g.	SCCA with B7H3/PD1		D. Zandberg
h.	RMS study with MLN0128		E. Slotkin
i.	Randomized phase II study testing impact of palliative care on phase I clinical trials		C. Blinderman
j.	Phase II study of SBRT + anti-PD1 (pembrolizumab) in advanced merkel cell carcinoma		J. Luke S. Chmura

4. Update on NCI Sponsored Match – *Schwartz*

5. Alliance Updates - *Horvath*

- AYA Sarcoma
 - COG presentation & discussion – R. Gorlick and D. Hawkins